Genencell said Tuesday that it asked the Ministry of Food and Drug Safety to authorize phase 2 and 3 clinical trials of ES16001, the company’s oral Covid-19 therapy. The company expects the domestic study to serve as a starting point for its global clinical trials of ES16001 in European countries.ES
SK Bioscience said its Covid-19 vaccine candidate GBP510 has recently received approval from the Vietnamese government to run phase 3 clinical trials, speeding up the development through global studies in five countries.The International Vaccine Institute (IVI), collaborating with SK Bioscience for
Domestic pharmaceutical companies are speeding up efforts to develop chimeric antigen receptor T (CAR-T) cell therapy after the government approved the first gene editing CAR-T treatment, Kymriah, this year, industry watchers said Thursday.Drugmakers are competing to develop the patient-tailored tre
The government has decided to expand home treatments for Covid-19 patients as a measure to prepare for gradually switching the nation’s infection control to return to the “live-with-covid” system early next month.The number of Covid-19 patients to treat symptoms at home has been significantly expand
Samsung Biologics has signed an agreement with Texas-based biotech company Enzolytics for developing and manufacturing monoclonal antibody therapy for Covid-19.Under the accord, Samsung Biologics will provide an end-to-end service to develop cell lines, manufacture clinical trial material, and apply
The 2021 International Congress of Diabetes and Metabolism (ICDM) kicked off its three-day online conference on Thursday. Sponsored by the Korean Diabetes Association (KDA), ICDM celebrates its 11th anniversary of discussing diabetes and endocrine systems.Notably, the conference put a lot of its foc
Biogen Korea said it would begin global phase 3 ASCEND trials of high-dose nusinersen, marketed as Spinraza, in treating patients with late-onset spinal muscular atrophy (SMA) who received Roche’s risdiplam in the past.It will conduct the second part of the ASCEND study for 2.5 years with 135 SMA pa
SK Biopharm has applied for a new global clinical trial plan of its epilepsy drug Xcopri (ingredient: cenobamate) to expand the treatment of pediatric patients.According to the U.S. National Institutes of Health, SK Biopharm submitted a new global phase 3 clinical trial plan of Xcopri. The study see
A research team of Yonsei Cancer Center (YCC) and Severance Hospital has reaffirmed the efficacy and safety of atezolizumab combined with etoposide and carboplatin as first-line therapy in small cell lung cancer (SCLC) patients. The research team, led by YCC Professor Hong Min-hee and Professor Lee
A domestic research team has presented a new standard to accurately evaluate the possibility of a nipple-areola preserving mastectomy in breast cancer patients.The research team, led by Professors Jeong Joon and Bae Sung-jun of the Surgical Department and Cha Yoon-jin of the Pathology Department at
Humedix has partnered up with a U.S. immuno-oncology developer Kineta to strengthen its CMO business and secure funding for future growth.The company said Tuesday that it has recently decided to sign a strategic investment deal with Kineta, acquiring 1.56 percent of the latter’s Kineta's shares wort
Roche Korea said Tuesday that it would expand the company’s neuroscience unit by receiving approval for its two mental disorder treatments -- Evrysdi (ingredient: risdiplam) and Enspryng (satralizumab) -- in five years.The company also stressed the importance of treating rare diseases, such as spina
Takeda Korea's oral treatment Ninlaro (ingredient: ixazomib) has won approval from the Ministry of Food and Drug Safety as maintenance therapy for patients with multiple myeloma who did not receive autologous hematopoietic stem cell transplant.Ninlaro became the first domestic oral proteasome inhibi
The K-Hospital Fair has completed its three-day event, introducing various sustainable, innovative digital healthcare solutions amid the prolonged Covid-19 pandemic and accelerating the digitization of the healthcare industry.Many Korean and foreign biotech companies developing digital healthcare so
Celltrion has submitted an application to obtain approval for CT-P16, a biosimilar of Roche's Avastin (ingredient: bevacizumab), for colorectal cancer treatment in the U.S. and Korea.The company completed global clinical trials of CT-P16 at 150 cites in 20 countries in Europe, South America, and Asi
Merck’s oral antiviral treatment for Covid-19, molnupiravir, has reportedly shown potential efficacy on the variants of the Covid-19 virus, causing Korean companies to speed up efforts to develop similar oral medicines.Merck, or MSD in the U.S. and Canada, said Wednesday its experimental Covid-19 th
Korea Research Institute of Chemical Technology (KRICT) said Thursday that an HIV treatment candidate developed by its team has been transferred to a domestic company and began sales in China as a new drug.The institute said that the drug candidate, once could have been thrown away, was transferred
The government said Thursday that it would provide various support for companies to develop at least one homegrown mRNA Covid-19 vaccine by 2023.Next year, it will spend 526.5 billion won ($444 million) to help drugmakers conduct clinical and non-clinical studies while pre-purchasing homegrown Covid
EOFlow has made the first shipment of the world's second wearable insulin pump, EOPatch, to the European market.EOPatch is a new-generation wearable insulin pump that succeeded in commercialization, solving the problem of long infusion lines in existing pumps, which had limited free movement for use
JW Pharmaceutical has begun marketing Livalozet, the first domestic combination drug of pitavastatin and ezetimibe, for treating dyslipidemia.The company said its dyslipidemia therapy doses are available in 2 or 4 milligrams of pitavastatin with 10 mg of ezetimibe. Medical professionals and patients